Shares of Qiagen NV (NASDAQ:QGEN) have been assigned a consensus rating of “Hold” from the seventeen research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $34.78.
Several analysts recently commented on the company. Goldman Sachs reiterated a “buy” rating on shares of Qiagen in a report on Wednesday. Commerzbank reiterated a “buy” rating on shares of Qiagen in a report on Wednesday, May 9th. Citigroup upped their target price on Qiagen from $31.00 to $35.00 and gave the company a “neutral” rating in a report on Friday, May 4th. BidaskClub upgraded Qiagen from a “hold” rating to a “buy” rating in a report on Wednesday, February 21st. Finally, JPMorgan Chase reiterated a “neutral” rating on shares of Qiagen in a report on Thursday, May 3rd.
NASDAQ:QGEN opened at $35.46 on Friday. The company has a current ratio of 5.07, a quick ratio of 4.59 and a debt-to-equity ratio of 0.69. Qiagen has a 1-year low of $30.20 and a 1-year high of $36.34.
Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Wednesday, May 2nd. The company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.02. The company had revenue of $343.60 million for the quarter, compared to analysts’ expectations of $339.30 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.22 earnings per share. equities analysts forecast that Qiagen will post 1.34 earnings per share for the current year.
Qiagen declared that its board has initiated a share repurchase program on Wednesday, January 31st that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.
Several institutional investors have recently bought and sold shares of QGEN. Nisa Investment Advisors LLC boosted its holdings in shares of Qiagen by 65.9% during the 4th quarter. Nisa Investment Advisors LLC now owns 21,401 shares of the company’s stock worth $662,000 after buying an additional 8,500 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of Qiagen by 13.7% during the 4th quarter. Bank of Montreal Can now owns 729,323 shares of the company’s stock worth $22,559,000 after buying an additional 87,790 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Qiagen by 3.8% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 207,993 shares of the company’s stock worth $6,434,000 after buying an additional 7,598 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Qiagen by 3.4% during the 4th quarter. Acadian Asset Management LLC now owns 412,888 shares of the company’s stock worth $12,770,000 after buying an additional 13,566 shares in the last quarter. Finally, State of Alaska Department of Revenue bought a new position in shares of Qiagen during the 4th quarter worth approximately $445,000. Hedge funds and other institutional investors own 62.23% of the company’s stock.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.